US FDA approves Regeneron-Sanofi’s Kevzara to treat polymyalgia rheumatica
The US Food and Drug Administration (FDA) has granted approval for Regeneron Pharmaceuticals and Sanofi’s Kevzara (sarilumab) to treat polymyalgia rheumatica (PMR) in adult patients. Kevzara has been approved as the first and only biologic indicated for PMR adult patients who did not respond to corticosteroids or who cannot tolerate corticosteroid taper. Developed using…...
Amgen Successfully Completes Acquisition of ChemoCentryx
TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., (Oct. 20, 2022) – Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat…...
